Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?

Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3.

Detalles Bibliográficos
Autores principales: Haj Najeeb, Bilal, Schmidt-Erfurth, Ursula
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Editorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275938/
https://www.ncbi.nlm.nih.gov/pubmed/36175488
http://dx.doi.org/10.1038/s41433-022-02249-2
_version_ 1785059971560374272
author Haj Najeeb, Bilal
Schmidt-Erfurth, Ursula
author_facet Haj Najeeb, Bilal
Schmidt-Erfurth, Ursula
author_sort Haj Najeeb, Bilal
collection PubMed
description Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3.
format Online
Article
Text
id pubmed-10275938
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-102759382023-06-18 Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration? Haj Najeeb, Bilal Schmidt-Erfurth, Ursula Eye (Lond) Editorial Given the wide spectrum of unique characteristics of macular neovascularization type 3 (MNV3) compared with types 1 and 2, we suggest regrading the colour photography assessment of the AREDS study to verify the impact of AREDS supplements on eyes with MNV3. Nature Publishing Group UK 2022-09-29 2023-06 /pmc/articles/PMC10275938/ /pubmed/36175488 http://dx.doi.org/10.1038/s41433-022-02249-2 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Editorial
Haj Najeeb, Bilal
Schmidt-Erfurth, Ursula
Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?
title Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?
title_full Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?
title_fullStr Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?
title_full_unstemmed Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?
title_short Do patients with unilateral macular neovascularization type 3 need AREDS supplements to slow the progression to advanced age-related macular degeneration?
title_sort do patients with unilateral macular neovascularization type 3 need areds supplements to slow the progression to advanced age-related macular degeneration?
topic Editorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10275938/
https://www.ncbi.nlm.nih.gov/pubmed/36175488
http://dx.doi.org/10.1038/s41433-022-02249-2
work_keys_str_mv AT hajnajeebbilal dopatientswithunilateralmacularneovascularizationtype3needaredssupplementstoslowtheprogressiontoadvancedagerelatedmaculardegeneration
AT schmidterfurthursula dopatientswithunilateralmacularneovascularizationtype3needaredssupplementstoslowtheprogressiontoadvancedagerelatedmaculardegeneration

Ejemplares similares